IL118487A0 - Heterocyclic ring-fused pyrimidine derivatives - Google Patents

Heterocyclic ring-fused pyrimidine derivatives

Info

Publication number
IL118487A0
IL118487A0 IL11848796A IL11848796A IL118487A0 IL 118487 A0 IL118487 A0 IL 118487A0 IL 11848796 A IL11848796 A IL 11848796A IL 11848796 A IL11848796 A IL 11848796A IL 118487 A0 IL118487 A0 IL 118487A0
Authority
IL
Israel
Prior art keywords
heterocyclic ring
pyrimidine derivatives
fused pyrimidine
fused
derivatives
Prior art date
Application number
IL11848796A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL118487A0 publication Critical patent/IL118487A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL11848796A 1995-06-07 1996-05-30 Heterocyclic ring-fused pyrimidine derivatives IL118487A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1995/007881 WO1996040142A1 (en) 1995-06-07 1995-06-07 Heterocyclic ring-fused pyrimidine derivatives
HU9601559A HUP9601559A3 (en) 1995-06-07 1996-06-06 Heterocyclic ring-fused pyrimidine derivatives, pharmaceutical compositions containing the same and intermediates

Publications (1)

Publication Number Publication Date
IL118487A0 true IL118487A0 (en) 1996-09-12

Family

ID=89994036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11848796A IL118487A0 (en) 1995-06-07 1996-05-30 Heterocyclic ring-fused pyrimidine derivatives

Country Status (32)

Country Link
EP (1) EP0831829B1 (xx)
JP (1) JP3290666B2 (xx)
CN (1) CN1141298A (xx)
AP (1) AP637A (xx)
AR (1) AR002746A1 (xx)
AT (1) ATE247469T1 (xx)
AU (1) AU5479196A (xx)
BR (1) BR9602695A (xx)
CA (1) CA2223081C (xx)
CO (1) CO4440628A1 (xx)
CZ (1) CZ164196A3 (xx)
DE (1) DE69531558T2 (xx)
DK (1) DK0831829T3 (xx)
ES (1) ES2203642T3 (xx)
FI (1) FI974443A0 (xx)
HR (1) HRP960269A2 (xx)
HU (1) HUP9601559A3 (xx)
IL (1) IL118487A0 (xx)
MA (1) MA26409A1 (xx)
MX (1) MX9709867A (xx)
NO (1) NO962386L (xx)
NZ (1) NZ286755A (xx)
OA (1) OA10460A (xx)
PL (1) PL314641A1 (xx)
PT (1) PT831829E (xx)
RU (1) RU2136683C1 (xx)
SG (1) SG45483A1 (xx)
SI (1) SI9600184A (xx)
SK (1) SK72996A3 (xx)
TR (1) TR199600474A2 (xx)
WO (1) WO1996040142A1 (xx)
ZA (1) ZA964725B (xx)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0682027B1 (de) * 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
TW321649B (xx) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
DK0819129T3 (da) * 1995-04-03 2000-10-23 Novartis Ag Pyrazolderivater og fremgangsmåde til deres fremstilling
EP0824525B1 (en) * 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2224435C (en) * 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997027199A1 (en) * 1996-01-23 1997-07-31 Novartis Ag Pyrrolopyrimidines and processes for their preparation
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-anilinochinazolin derivate
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
WO1997049706A1 (en) * 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
ATE384062T1 (de) 1996-08-23 2008-02-15 Novartis Pharma Gmbh Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
AU720135B2 (en) 1996-10-02 2000-05-25 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
JP2000505109A (ja) * 1996-11-27 2000-04-25 ファイザー・インク 縮合二環式ピリミジン誘導体
CA2303280A1 (en) * 1997-09-02 1999-03-11 Rajagopal Bakthavatchalam Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
JP2001522853A (ja) * 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
JPH11236333A (ja) * 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
ATE265458T1 (de) * 1998-06-19 2004-05-15 Pfizer Prod Inc Pyrrolo(2,3-d)pyrimidin-verbindungen
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6174903B1 (en) 1998-12-28 2001-01-16 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
EP1192151B1 (en) 1999-07-09 2007-11-07 Glaxo Group Limited Anilinoquinazolines as protein tyrosine kinase inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
OA12010A (en) * 1999-09-15 2006-04-19 Warner Lambert Co Pteridinones as kinase inhibitors.
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
SK287401B6 (sk) 1999-11-05 2010-09-07 Astrazeneca Ab Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
JP2001142235A (ja) 1999-11-17 2001-05-25 Fuji Denki Gazo Device Kk 電子写真用感光体
DK1235830T3 (da) 1999-12-10 2004-03-29 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
JP2003535867A (ja) 2000-06-06 2003-12-02 ファイザー プロダクツ インコーポレイテッド 抗癌剤として有用なチオフェン誘導体
MXPA03000068A (es) 2000-06-26 2003-09-25 Pfizer Prod Inc Compuestos de pirrolo (2,3-d)pirimidina como agentes inmunosupresores.
HUP0302221A3 (en) 2000-09-20 2004-01-28 Merck Patent Gmbh 4-amino-quinazolines
PT1415987E (pt) 2000-10-20 2007-05-31 Eisai R&D Man Co Ltd Compostos contendo aneis aromáticos azotados utilizados como agentes anti-cancerígenos.
DE60212487T2 (de) 2001-04-13 2006-12-21 Pfizer Products Inc., Groton Bizyklisch substituierte 4-Aminopyridopyrimidinderivate
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
MXPA04006882A (es) 2002-01-17 2004-12-06 Neurogen Corp Analogos substituidos de quinazolin-4-ilamina como moduladores de receptores de capsaicina.
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
DE60318177T2 (de) 2002-01-23 2008-10-09 Bayer Pharmaceuticals Corp., West Haven Rho-kinase inhibitoren
JP2003238561A (ja) 2002-02-13 2003-08-27 Fuji Denki Gazo Device Kk キノメタン化合物
BR0308162A (pt) 2002-03-01 2004-12-07 Pfizer Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004047843A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
EP1610778A4 (en) 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF BENIGNER PROSTATE HYPERPLASIA
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
OA13170A (en) 2003-05-22 2006-12-13 Pharmacia Italia Spa Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
CA2535620A1 (en) * 2003-08-15 2005-02-24 Irm Llc 6-substituted anilino purines as rtk inhibitors
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
ATE412655T1 (de) 2003-08-29 2008-11-15 Pfizer Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
JPWO2005095419A1 (ja) * 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
MXPA06013805A (es) 2004-05-27 2007-02-02 Pfizer Prod Inc Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
WO2005118588A1 (ja) * 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited 縮合複素環化合物
ZA200610669B (en) * 2004-06-02 2008-06-25 Takeda Pharmaceutical Fused heterocyclic compound
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
CN101124228B (zh) * 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 用作抗肿瘤药物的吡唑并嘧啶化合物
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
JP2008531542A (ja) * 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 抗癌剤として有用な二環式複素芳香族誘導体
SI1899334T1 (sl) * 2005-06-17 2009-04-30 Janssen Pharmaceutica Nv Naftiridinske spojine
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
DE602006015861D1 (de) 2005-12-21 2010-09-09 Abbott Lab Antivirale verbindungen
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
KR20090017498A (ko) * 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US20090233937A1 (en) 2008-03-12 2009-09-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
UA101676C2 (uk) 2008-07-31 2013-04-25 Дженентек, Инк. Піримідинові сполуки, композиції і способи застосування
MX2011001904A (es) 2008-08-20 2011-03-29 Pfizer Compuestos de pirrolo[2,3-d]pirimidina.
TW201014860A (en) * 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
KR101126736B1 (ko) * 2008-11-27 2012-04-12 주식회사 레고켐 바이오사이언스 티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물
KR102088588B1 (ko) 2009-01-16 2020-03-12 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
DE102009005193A1 (de) * 2009-01-20 2010-07-22 Merck Patent Gmbh Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
WO2010094695A1 (en) * 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
KR101469334B1 (ko) 2009-11-12 2014-12-04 에프. 호프만-라 로슈 아게 Ｎ-9-치환된 퓨린 화합물, 조성물 및 사용 방법
WO2011058025A1 (en) 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
MX2012009074A (es) * 2010-02-05 2012-08-23 Pfizer Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
SG187956A1 (en) * 2010-08-27 2013-03-28 Merck Patent Gmbh Furopyridine derivatives
WO2012080990A1 (en) 2010-12-17 2012-06-21 Nerviano Medical Sciences S.R.L. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
CN103998040B (zh) 2011-03-04 2017-03-29 江苏康缘药业股份有限公司 炔基取代的喹唑啉化合物及其使用方法
BR112013021941B1 (pt) 2011-04-18 2022-11-16 Eisai R & D Management Co., Ltd Agente terapêutico para tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013124025A1 (en) * 2012-02-21 2013-08-29 Merck Patent Gmbh Furopyridine derivatives
CN104781260A (zh) 2012-09-26 2015-07-15 拜耳制药股份公司 用于治疗过度增殖性障碍的取代的吲唑-吡咯并嘧啶
CA2885783A1 (en) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
CA2889866A1 (en) 2012-12-21 2014-06-26 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
JP2016506944A (ja) * 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
NZ729137A (en) 2014-08-04 2022-07-29 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
EP3524595B1 (en) 2014-08-28 2022-08-10 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
GB201520499D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
WO2021124277A1 (en) 2019-12-20 2021-06-24 Nuevolution A/S Compounds active towards nuclear receptors
AU2021249530A1 (en) 2020-03-31 2022-12-01 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
KR20230170039A (ko) 2021-04-13 2023-12-18 뉴베일런트, 아이엔씨. Egfr 돌연변이를 지니는 암을 치료하기 위한 아미노-치환된 헤테로사이클

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012513A (en) * 1971-11-03 1977-03-15 Imperial Chemical Industries Limited Indole derivatives for providing analgesic and anti-inflammatory effects
JPS58126887A (ja) * 1981-09-26 1983-07-28 Takeda Chem Ind Ltd 新規７−デアザプリン誘導体
JPS58157790A (ja) * 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ７−デアザプリン誘導体およびその製造法
JPS60233080A (ja) * 1984-05-02 1985-11-19 Takeda Chem Ind Ltd ７−デアザプリン誘導体
IE60433B1 (en) * 1986-08-26 1994-07-13 Warner Lambert Co Novel 9-deazaguanines
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DK0495982T3 (da) * 1989-10-11 1996-07-01 Teijin Ltd Bicyklisk pyrimidinderivat, fremgangsmåde til fremstilling deraf og farmaceutisk præparat omfattende dette som en aktiv bestanddel
US5320663A (en) * 1992-07-02 1994-06-14 E. I. Du Pont De Nemours And Company Method of obtaining lead and organolead from contaminated media using metal accumulating plants
KR0173172B1 (ko) * 1992-12-17 1999-02-01 알렌 제이. 스피겔 Crf 길항제로서의 피롤로피리미딘
AU6855594A (en) * 1993-06-30 1995-01-24 Biocryst Pharmaceuticals, Inc. 9-deazahypoxanthines as pnp inhibitors

Also Published As

Publication number Publication date
BR9602695A (pt) 1998-10-06
CA2223081A1 (en) 1996-12-19
NZ286755A (en) 1998-03-25
CZ164196A3 (en) 1996-12-11
ZA964725B (en) 1997-12-08
HUP9601559A3 (en) 1997-07-28
EP0831829A1 (en) 1998-04-01
SG45483A1 (en) 1998-01-16
DE69531558T2 (de) 2004-03-18
PL314641A1 (en) 1996-12-09
EP0831829A4 (en) 1998-11-25
NO962386D0 (no) 1996-06-06
RU2136683C1 (ru) 1999-09-10
HUP9601559A2 (en) 1997-02-28
JPH10508875A (ja) 1998-09-02
FI974443A (fi) 1997-12-05
NO962386L (no) 1996-12-09
ATE247469T1 (de) 2003-09-15
AU5479196A (en) 1996-12-19
MA26409A1 (fr) 2004-12-20
ES2203642T3 (es) 2004-04-16
AR002746A1 (es) 1998-04-29
AP637A (en) 1998-04-08
CO4440628A1 (es) 1997-05-07
JP3290666B2 (ja) 2002-06-10
HRP960269A2 (en) 1997-08-31
PT831829E (pt) 2003-12-31
TR199600474A2 (tr) 1996-12-21
OA10460A (en) 2002-03-28
WO1996040142A1 (en) 1996-12-19
CA2223081C (en) 2001-03-06
CN1141298A (zh) 1997-01-29
MX9709867A (es) 1998-03-31
SK72996A3 (en) 1997-04-09
FI974443A0 (fi) 1997-12-05
SI9600184A (en) 1997-04-30
DE69531558D1 (de) 2003-09-25
AP9600805A0 (en) 1996-07-31
DK0831829T3 (da) 2003-12-15
EP0831829B1 (en) 2003-08-20
HU9601559D0 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
HU9601559D0 (en) Heterocyclic ring-fused pyrimidine derivatives
IL131521A0 (en) Pyrimidine derivatives
IL123581A0 (en) Pyrimidine derivatives as 5HT2c- receptor antagonists
GB9309716D0 (en) Heterocyclic derivatives
AU1687699A (en) Nitrogenous heterocyclic derivatives
GB9311562D0 (en) Heterocyclic derivatives
HU9503012D0 (en) New pyrimidine derivatives
ZA961954B (en) Heterocyclic substituted piperazinone derivatives
AU3467197A (en) Tetracyclical derivatives from pyrimidine
ZA948297B (en) Pyrimidine derivatives
ZA965746B (en) Pyrimidine nucleoside derivative
GB9606264D0 (en) Pyrimidine nucleoside derivatives
GB9623283D0 (en) Heterocyclic derivatives
GB9511098D0 (en) Heterocyclic derivatives
GB9502610D0 (en) Heterocyclic derivatives
GB9511052D0 (en) Heterocyclic derivatives
GB9519666D0 (en) Heterocyclic derivatives
ZA965747B (en) Pyrimidine nucleoside derivatives
EP0954316A4 (en) PYRIMIDINE DERIVATIVES
AU696216C (en) Pyrimidine derivatives
GB9715893D0 (en) Heterocyclic derivatives
GB9715970D0 (en) Heterocyclic derivatives
GB9602145D0 (en) Heterocyclic derivatives
GB9626857D0 (en) Heterocyclic derivatives
GB9722377D0 (en) Heterocyclic derivatives